HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
- 9 January 2020
- journal article
- review article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 68 (1), 1-18
- https://doi.org/10.1007/s00005-019-00566-1
Abstract
Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically improved by understanding of the immune regulatory mechanisms of tumor microenvironment. Passive immunotherapy utilizing recombinant monoclonal antibodies (mAbs), particularly trastuzumab and pertuzumab has proved to be an effective strategy in HER2-positive breast cancer treatment. However, resistance to mAb therapy and relapse of disease are still considered important challenges in clinical practice. There are increasing reports on the induction of cellular and humoral immune responses in HER2-positive breast cancer patients. More recently, increasing efforts are focused on using HER2-derived peptide vaccines for active immunotherapy. Here, we discuss the development of various HER2-derived vaccines tested in animal models and human clinical trials. Different formulations and strategies to improve immunogenicity of the antigens in animal studies are also discussed. Furthermore, other immunotherapeutic approaches to HER2 breast cancer including, CTLA-4 inhibitors, immune checkpoint inhibitors, anti PD-1/PD-L1 antibodies are presented.This publication has 157 references indexed in Scilit:
- Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responsesCancer Gene Therapy, 2013
- Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive CancersFrontiers in Oncology, 2013
- CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APCCancer Gene Therapy, 2012
- Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensVaccine, 2012
- CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor modelCancer Gene Therapy, 2011
- Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patientsCancer, 2011
- Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer modelCell Stress and Chaperones, 2010
- Nanoparticle Delivery Systems in Cancer VaccinesPharmaceutical Research, 2010
- Anti-HER2 vaccines: new prospects for breast cancer therapyCancer Immunology, Immunotherapy, 2010
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004